Keywords: gsk, rls, drug, well-tolerated, uk, major, glaxosmithkline
GSK's RLS drug is well-tolerated
Article | 28 April 2008
UK drug major GlaxoSmithKline says that data from the first pivotal study of XP13512/GSK1838262, a sustained-release investigational agent for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
